Publicacións en colaboración con investigadores/as de AstraZeneca (United Kingdom) (1)

2024

  1. Tezepelumab decreases airway epithelial IL-33 and T2-inflammation in response to viral stimulation in patients with asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 3, pp. 656-666